EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung cancer (NSCLC), highlighting the importance of biomarker-driven targeted therapies in this indication. EGFR tyrosine kinase inhibitors (TKIs)—Tarceva (Roche/ Genentech), Iressa (AstraZeneca), Tagrisso (AstraZeneca), and Gilotrif/Giotrif (Boehringer Ingelheim)—have been the conventional first-line choice of therapy in EGFR-mutation-positive metastatic nonsquamous NSCLC for many years. In 2018, the next-generation EGFR TKI Vizimpro (Pfizer) was approved in the United States for the first-line treatment of patients with EGFR mutations. The PD-1 inhibitor Opdivo (Bristol-Myers Squibb) for treatment of EGFR-mutation-positive metastatic nonsquamous NSCLC is another option for patients who have progressed on EGFR TKIs. However, resistance to EGFR TKIs and treatment-related adverse events remain key unmet needs in the metastatic setting, generating opportunity for novel therapies to gain an upper hand over the existing drugs in the NSCLC treatment landscape.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 medical oncologists in US and 30 medical oncologists in Europe fielded in March 2019.
Key companies: Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Pfizer, Teva.
Key drugs: Tarceva, Iressa, Gilotrif/Giotrif, Tagrisso, Vizimpro, Avastin (in combination with paclitaxel and carboplatin), Opdivo.